Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'
- PMID: 32737114
- DOI: 10.1136/annrheumdis-2020-218365
Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'
Keywords: antirheumatic agents; arthritis, rheumatoid; biological therapy.
Conflict of interest statement
Competing interests: AP-S and JD are employees of F. Hoffmann-La Roche. WR is an employee of Genentech.
Comment in
-
Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'' by Pethoe-Schramm et al.Ann Rheum Dis. 2022 Aug;81(8):e137. doi: 10.1136/annrheumdis-2020-218403. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737110 No abstract available.
Comment on
-
Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.Ann Rheum Dis. 2020 Jul;79(7):874-882. doi: 10.1136/annrheumdis-2019-215987. Epub 2020 May 5. Ann Rheum Dis. 2020. PMID: 32371387
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
